mequitazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1707 | 29216-28-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| fu (Fraction unbound in plasma) | 0.04 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis and uveitis syndrome | 55.84 | 46.13 | 6 | 49 | 239 | 63488728 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis and uveitis syndrome | 46.00 | 36.96 | 6 | 243 | 329 | 79743810 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R06AD07 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives |
| MeSH PA | D018494 | Histamine Agents |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006634 | Histamine H1 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.22 | Basic |
| pKa2 | 3.55 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | GPCR | Ki | 8.24 | PDSP | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.25 | PDSP | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.85 | PDSP | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 8.28 | PDSP | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.96 | PDSP | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.96 | PDSP | |||||
| Trypanothione reductase | Enzyme | IC50 | 4.66 | CHEMBL | |||||
| Histamine H1 receptor | GPCR | Ki | 8 | CHEMBL | |||||
| Trypanothione reductase | Enzyme | IC50 | 4.27 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01324 | KEGG_DRUG |
| C0065972 | UMLSCUI |
| CHEBI:31821 | CHEBI |
| CHEMBL73451 | ChEMBL_ID |
| CHEMBL1908311 | ChEMBL_ID |
| DB01071 | DRUGBANK_ID |
| C006069 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4066 | PUBCHEM_CID |
| 3672 | INN_ID |
| Y463242LY2 | UNII |
| 29528 | RXNORM |
| 004003 | NDDF |
| 320756004 | SNOMEDCT_US |
| 414674005 | SNOMEDCT_US |
Pharmaceutical products:
None